BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23715301)

  • 21. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.
    Miller KL; Marks LB; Sibley GS; Clough RW; Garst JL; Crawford J; Shafman TD
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):355-9. PubMed ID: 12738309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
    Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer.
    Ge XH; Lin Q; Ren XC; Liu YE; Chen XJ; Wang DY; Wang YQ; Cao B; Li ZG; Liu ML
    Radiat Oncol; 2013 Oct; 8():238. PubMed ID: 24125485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irinotecan plus cisplatin chemotherapy followed by concurrent thoracic irradiation with low-dose weekly cisplatin for limited-disease small-cell lung cancer.
    Wahba HA; Halim AA; El-Hadaad HA
    Med Oncol; 2012 Mar; 29(1):199-204. PubMed ID: 21140241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer : A single-centre retrospective study.
    Sas-Korczyńska B; Łuczyńska E; Kamzol W; Sokołowski A
    Strahlenther Onkol; 2017 Feb; 193(2):141-149. PubMed ID: 27785518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.
    Choy H; Schwartzberg LS; Dakhil SR; Garon EB; Gerber DE; Choksi JK; Govindan R; Peng G; Koustenis A; Treat J; Obasaju C
    J Thorac Oncol; 2013 Oct; 8(10):1308-16. PubMed ID: 23981966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer].
    Wang D; Xu L; Zhao L; Zhang W; Pang Q; Liu N; Chen X; Chen X; Yuan Z; Wang P
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):871-878. PubMed ID: 27978874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.
    Christodoulou M; Blackhall F; Mistry H; Leylek A; Knegjens J; Remouchamps V; Martel-Lafay I; Farré N; Zwitter M; Lerouge D; Pourel N; Janicot H; Scherpereel A; Tissing-Tan C; Peignaux K; Geets X; Konopa K; Faivre-Finn C
    J Thorac Oncol; 2019 Jan; 14(1):63-71. PubMed ID: 30391573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypofractionated conformal radiotherapy in combination with chemotherapy in limited disease small cell lung cancer patients.
    Socha J; Guzowska A; Tyc-Szczepaniak D; Szczęsna A; Kępka L
    Pneumonol Alergol Pol; 2014; 82(2):105-15. PubMed ID: 24615194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
    Morimoto M; Okishio K; Akira M; Omachi N; Tamiya A; Asami K; Kawaguchi T; Atagi S
    Clin Lung Cancer; 2017 Mar; 18(2):e117-e127. PubMed ID: 28340925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.
    Gazula A; Baldini EH; Chen A; Kozono D
    Lung; 2014 Feb; 192(1):151-8. PubMed ID: 24162870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival.
    Watkins JM; Wahlquist AE; Zauls AJ; Shirai K; Garrett-Mayer E; Aguero EG; Silvestri GA; Sherman CA; Sharma AK
    J Med Imaging Radiat Oncol; 2010 Oct; 54(5):483-9. PubMed ID: 20958948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent versus sequential chemotherapy and radiotherapy in limited disease small cell lung cancer: a retrospective comparative study.
    El Sharouni SY; Kal HB; Barten-Van Rijbroek A; Struikmans H; Battermann JJ; Schramel FM
    Anticancer Res; 2009 Dec; 29(12):5219-24. PubMed ID: 20044639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.
    Le Péchoux C; Dunant A; Senan S; Wolfson A; Quoix E; Faivre-Finn C; Ciuleanu T; Arriagada R; Jones R; Wanders R; Lerouge D; Laplanche A;
    Lancet Oncol; 2009 May; 10(5):467-74. PubMed ID: 19386548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.